Business

Biocoin Consolidated Net Profit Plunge Over 18 Percent In Second Quarter

According to Biocoin statement, in the second quarter, the revenue from operations grew five per cent to Rs 1,840 crore from Rs 1,750 crore in the year-ago period.

Sentinel Digital Desk

New Delhi: Biotechnology major Biocon on Friday said its consolidated net profit declined 18 per cent to Rs 138 crore for the second quarter of the current financial year ended September 30.

In July-September quarter in the last fiscal, the Bengaluru-based company had reported a net profit of Rs 169 crore.

According to Biocoin statement, in the second quarter, the revenue from operations grew five per cent to Rs 1,840 crore from Rs 1,750 crore in the year-ago period.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Ltd., said, "With the impact of the pandemic easing and supply chain conditions improving, I believe all three segments of the business – generics, biosimilars and research services – are expected to grow for the financial year 2021-22. We are in the right position for sustainable growth in the second half of the year (October 2021-March 2022)."

The company said it has made arrangements under a special clause in Biocon Biologics to reverse the claims of an alternative variable bond amendment and an old-term Export Services Incentive Scheme (SEIS).

The company believes that its entry into vaccines and anitbodies will proved to be growth driver for its subsdiary Biocoin Bilogics.

Notably, the company has entered into strategic alliance with Serum institute Life Sciences (SILS) which will provide the company as asset light and accelerated entry into the vaccines segment.

Also watch: